United Kingdom-based AstraZeneca has started a phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine intended to decrease blood cholesterol levels in patients with dyslipidemia, it was reported on Monday.
The product is a LIgand Conjugated Antisense medicine being developed in collaboration with United States-based Ionis Pharmaceuticals Inc. It targets proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol.
The Phase 2b, randomised, double-blind, placebo-controlled trial is enrolling around 108 participants between the age of 18 to 75 years, who have low-density lipoprotein cholesterol levels between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin therapy as defined by the American College of Cardiology/American Heart Association guidelines on blood cholesterol management. The main aim is to evaluate the effect of different doses of the product on LDL-C compared to placebo at Week 12 in patients taking baseline statin therapy. The study is to assess three dose levels of the product compared to the placebo, all administered once a month by subcutaneous injection. Safety and tolerability will be evaluated along with a number of secondary endpoints.
Gentian Diagnostics' SARS-CoV-2 test moves to optimisation phase
ViiV Healthcare wins FDA approval for HIV treatment Cabenuva
Incyte granted FDA priority review for retifanlimab BLA for SCAC
Cerba Research reports launch of time-saving COVID-19 exploratory tools and NGS advancements
Brigham Young University announces alcohol free Disinfect & Shield kills COVID-19 on contact
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
FDA Grants Priority Review to Genentech's Esbriet for Unclassifiable Interstitial Lung Disease
Turn Therapeutics Authorized to Start Human Trial for COVID-19 Therapeutic Candidate
First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
VBI Vaccines Updates Progress of Coronavirus Vaccine Program
EuBiologics Receives IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea
Enhertu Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer